Annual CFO
-$38.58 M
-$19.93 M-106.85%
31 December 2023
Summary:
Verrica Pharmaceuticals annual cash flow from operations is currently -$38.58 million, with the most recent change of -$19.93 million (-106.85%) on 31 December 2023. During the last 3 years, it has fallen by -$8.37 million (-27.71%). VRCA annual CFO is now -2294.60% below its all-time high of -$1.61 million, reached on 31 December 2016.VRCA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$8.56 M
+$7.80 M+47.68%
30 September 2024
Summary:
Verrica Pharmaceuticals quarterly cash flow from operations is currently -$8.56 million, with the most recent change of +$7.80 million (+47.68%) on 30 September 2024. Over the past year, it has increased by +$6.25 million (+42.22%). VRCA quarterly CFO is now -442.46% below its all-time high of $2.50 million, reached on 30 June 2021.VRCA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$59.37 M
+$6.25 M+9.53%
30 September 2024
Summary:
Verrica Pharmaceuticals TTM cash flow from operations is currently -$59.37 million, with the most recent change of +$6.25 million (+9.53%) on 30 September 2024. Over the past year, it has dropped by -$30.35 million (-104.55%). VRCA TTM CFO is now -11564.05% below its all-time high of -$509.00 thousand, reached on 31 March 2017.VRCA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRCA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -106.8% | +42.2% | -104.5% |
| 3 y3 years | -27.7% | +19.3% | -137.6% |
| 5 y5 years | -115.8% | -18.4% | -127.5% |
VRCA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -106.8% | at low | -568.9% | +57.1% | -379.3% | +9.5% |
| 5 y | 5 years | -115.8% | at low | -442.5% | +57.1% | -379.3% | +9.5% |
| alltime | all time | -2294.6% | at low | -442.5% | +57.1% | <-9999.0% | +9.5% |
Verrica Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.56 M(-47.7%) | -$59.37 M(-9.5%) |
| June 2024 | - | -$16.36 M(-18.0%) | -$65.62 M(+21.7%) |
| Mar 2024 | - | -$19.95 M(+37.5%) | -$53.93 M(+39.8%) |
| Dec 2023 | -$38.58 M(+106.8%) | -$14.51 M(-2.1%) | -$38.58 M(+32.9%) |
| Sept 2023 | - | -$14.81 M(+217.2%) | -$29.02 M(+134.3%) |
| June 2023 | - | -$4.67 M(+1.7%) | -$12.39 M(-16.9%) |
| Mar 2023 | - | -$4.59 M(-7.3%) | -$14.90 M(-20.1%) |
| Dec 2022 | -$18.65 M(-32.4%) | -$4.95 M(-371.5%) | -$18.65 M(-16.7%) |
| Sept 2022 | - | $1.82 M(-125.4%) | -$22.39 M(-35.7%) |
| June 2022 | - | -$7.18 M(-13.9%) | -$34.82 M(+38.5%) |
| Mar 2022 | - | -$8.34 M(-4.1%) | -$25.14 M(-8.9%) |
| Dec 2021 | -$27.58 M(-8.7%) | -$8.70 M(-17.9%) | -$27.58 M(+10.4%) |
| Sept 2021 | - | -$10.60 M(-524.1%) | -$24.98 M(+13.6%) |
| June 2021 | - | $2.50 M(-123.2%) | -$21.99 M(-33.5%) |
| Mar 2021 | - | -$10.79 M(+76.8%) | -$33.09 M(+9.5%) |
| Dec 2020 | -$30.21 M | -$6.10 M(-19.8%) | -$30.21 M(-6.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$7.61 M(-11.5%) | -$32.32 M(+1.2%) |
| June 2020 | - | -$8.59 M(+8.7%) | -$31.94 M(+12.5%) |
| Mar 2020 | - | -$7.91 M(-3.7%) | -$28.40 M(+3.6%) |
| Dec 2019 | -$27.41 M(+53.3%) | -$8.21 M(+13.6%) | -$27.41 M(+5.0%) |
| Sept 2019 | - | -$7.23 M(+43.1%) | -$26.10 M(+8.7%) |
| June 2019 | - | -$5.05 M(-27.0%) | -$24.01 M(+6.1%) |
| Mar 2019 | - | -$6.92 M(+0.2%) | -$22.64 M(+26.6%) |
| Dec 2018 | -$17.87 M(+290.0%) | -$6.90 M(+34.4%) | -$17.87 M(+39.4%) |
| Sept 2018 | - | -$5.14 M(+39.6%) | -$12.82 M(+46.4%) |
| June 2018 | - | -$3.68 M(+70.8%) | -$8.76 M(+40.6%) |
| Mar 2018 | - | -$2.15 M(+16.6%) | -$6.23 M(+35.9%) |
| Dec 2017 | -$4.58 M(+184.5%) | -$1.85 M(+71.8%) | -$4.58 M(+67.5%) |
| Sept 2017 | - | -$1.07 M(-6.7%) | -$2.74 M(+64.7%) |
| June 2017 | - | -$1.15 M(+126.3%) | -$1.66 M(+226.3%) |
| Mar 2017 | - | -$509.00 K | -$509.00 K |
| Dec 2016 | -$1.61 M | - | - |
FAQ
- What is Verrica Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals annual CFO year-on-year change?
- What is Verrica Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals quarterly CFO year-on-year change?
- What is Verrica Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals TTM CFO year-on-year change?
What is Verrica Pharmaceuticals annual cash flow from operations?
The current annual CFO of VRCA is -$38.58 M
What is the all time high annual CFO for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high annual cash flow from operations is -$1.61 M
What is Verrica Pharmaceuticals annual CFO year-on-year change?
Over the past year, VRCA annual cash flow from operations has changed by -$19.93 M (-106.85%)
What is Verrica Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of VRCA is -$8.56 M
What is the all time high quarterly CFO for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high quarterly cash flow from operations is $2.50 M
What is Verrica Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, VRCA quarterly cash flow from operations has changed by +$6.25 M (+42.22%)
What is Verrica Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of VRCA is -$59.37 M
What is the all time high TTM CFO for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high TTM cash flow from operations is -$509.00 K
What is Verrica Pharmaceuticals TTM CFO year-on-year change?
Over the past year, VRCA TTM cash flow from operations has changed by -$30.35 M (-104.55%)